Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06276933
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-26
First Post:
2024-02-16
Brief Title:
A Study of Camrelizumab Combined With Chemotherapy Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer NSCLC
Sponsor:
Tongji University
Organization:
Tongji University
Study Overview
Official Title:
A Prospective Multicenter Double-blind Randomized Controlled Study of Camrelizumab Combined With Chemotherapy Thalidomide in First-line Treatment of Patients With Advanced NSCLC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore and evaluate the safety and efficacy of camrelizumab combined with chemotherapy thalidomide in first-line treatment of advanced non-small cell lung cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None